| 66 Long-acting protein drugs for the treatment of ocular diseases.
65 An artificial intelligence platform for the multihospital collaborative management of congenital cataracts.
64 Oral supplementation with vitamin B3 protects against glaucoma development in mice.
63 Mobile zinc increases rapidly in the retina after optic nerve injury and regulates ganglion cell survival and optic nerve regeneration.
62 Adalimumab in Patients with Active Noninfectious Uveitis.
61 Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids.
60 PACAP suppresses dry eye signs by stimulating tear secretion.
59 Transplantation of iPSC-derived TM cells rescues glaucoma phenotypes in vivo.
58 Co-ordinated ocular development from human iPS cells and recovery of corneal function.
57 Lens regeneration using endogenous stem cells with gain of visual function.
56 IL-33 amplifies an innate immune response in the degenerating retina.
55 Improving the spatial resolution of epiretinal implants by increasing stimulus pulse duration.
54 Transgenic expression of the proneural transcription factor Ascl1 in Müller glia stimulates retinal regeneration in young mice.
53 A compound that reverses the molecular cause of cataract formation improves eye lens transparency in mice.
52 Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.
51 The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.
50 Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site.
49 A short N-terminal domain of HDAC4 preserves photoreceptors and restores visual function in retinitis pigmentosa.
48 Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury.
47 Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis.